文献速递神经MR

NAA是继发进展型多发性硬化残疾的标志物:质子MR波谱成像研究

NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-11-05

该横断面研究纳入119例继发进展型多发性硬化患者,采用1H-MRS成像测量正常表现白质和灰质中总NAA、mIns、Glx、总Cho的估计浓度及与总Cr的比值,分析其与身体和认知残疾量表的关系。结果显示正常表现白质中tNAA/tCr与九孔 peg 测试相关(ρ=0.23),tNAA及tNAA/tCr与PASAT相关(ρ=0.21、0.19),mIns/tCr与PASAT相关(ρ=-0.23),灰质中tCho与PASAT相关(ρ=-0.24),提示神经轴索完整性、星形胶质增生和膜周转的代谢标志物可能作为继发进展型多发性硬化残疾的标志物。

要点

  • 正常表现白质tNAA/tCr与九孔 peg 测试呈正相关(ρ=0.23),tNAA及tNAA/tCr与PASAT呈正相关(ρ=0.21、0.19)。
  • 正常表现白质mIns/tCr与PASAT呈负相关(ρ=-0.23),灰质tCho与PASAT呈负相关(ρ=-0.24)。
  • 初始相关分析中其他有意义的关联经多元线性回归后失去显著性。

核心结论

  • 本研究提示正常表现白质中神经轴索完整性和星形胶质增生的代谢标志物以及灰质中膜周转的标志物可能作为继发进展型多发性硬化的残疾标志物。

研究设计与样本

  • 横断面分析,纳入119例继发进展型多发性硬化患者,采用1H-MRS成像获取正常表现白质和灰质中总NAA、mIns、Glx和总Cho的估计浓度及与总Cr的比值。
  • 临床结局指标包括PASAT、SDMT、九孔 peg 测试、定时25英尺步行测试和EDSS;先以Spearman秩相关分析,显著关联再纳入多元回归模型校正年龄、性别、病程、T2病灶负荷、归一化脑体积及入组前2年内复发。

诊断标准与关键数值

  • 正常表现白质中tNAA/tCr与九孔 peg 测试相关(ρ=0.23;95%CI 0.06-0.40)。
  • 正常表现白质中tNAA与PASAT相关(ρ=0.21;95%CI 0.03-0.38),tNAA/tCr与PASAT相关(ρ=0.19;95%CI 0.01-0.36)。
  • 正常表现白质中mIns/tCr与PASAT相关(ρ=-0.23;95%CI -0.39至-0.05)。
  • 灰质中tCho与PASAT相关(ρ=-0.24;95%CI -0.40至-0.06)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The secondary progressive phase of multiple sclerosis is characterised by disability progression due to processes that lead to neurodegeneration. Surrogate markers such as those derived from MRI are beneficial in understanding the pathophysiology that drives disease progression and its relationship to clinical disability. We undertook a 1H-MRS imaging study in a large secondary progressive MS (SPMS) cohort, to examine whether metabolic markers of brain injury are associated with measures of disability, both physical and cognitive.

MATERIALS AND METHODS: A cross-sectional analysis of individuals with secondary-progressive MS was performed in 119 participants. They underwent 1H-MR spectroscopy to obtain estimated concentrations and ratios to total Cr for total NAA, mIns, Glx, and total Cho in normal-appearing WM and GM. Clinical outcome measures chosen were the following: Paced Auditory Serial Addition Test, Symbol Digit Modalities Test, Nine-Hole Peg Test, Timed 25-foot Walk Test, and the Expanded Disability Status Scale. The relationship between these neurometabolites and clinical disability measures was initially examined using Spearman rank correlations. Significant associations were then further analyzed in multiple regression models adjusting for age, sex, disease duration, T2 lesion load, normalized brain volume, and occurrence of relapses in 2 years preceding study entry.

RESULTS: Significant associations, which were then confirmed by multiple linear regression, were found in normal-appearing WM for total NAA (tNAA)/total Cr (tCr) and the Nine-Hole Peg Test (ρ = 0.23; 95% CI, 0.06-0.40); tNAA and tNAA/tCr and the Paced Auditory Serial Addition Test (ρ = 0.21; 95% CI, 0.03-0.38) (ρ = 0.19; 95% CI, 0.01-0.36); mIns/tCr and the Paced Auditory Serial Addition Test, (ρ = -0.23; 95% CI, -0.39 to -0.05); and in GM for tCho and the Paced Auditory Serial Addition Test (ρ = -0.24; 95% CI, -0.40 to -0.06). No other GM or normal-appearing WM relationships were found with any metabolite, with associations found during initial correlation testing losing significance after multiple linear regression analysis.

CONCLUSIONS: This study suggests that metabolic markers of neuroaxonal integrity and astrogliosis in normal-appearing WM and membrane turnover in GM may act as markers of disability in secondary-progressive MS.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Solanky BS, John NA, DeAngelis F, et al. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. AJNR Am J Neuroradiol. 2020. PMID: 33154071. doi:10.3174/ajnr.A6809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。